NSPR - InspireMD, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.17230
-0.01040 (-5.69%)
At close: 3:52PM EDT

0.17380 0.00 (0.75%)
After hours: 4:03PM EDT

Stock chart is not supported by your current browser
Previous Close0.18270
Open0.17600
Bid0.17220 x 1000
Ask0.17230 x 4000
Day's Range0.17040 - 0.17920
52 Week Range0.12000 - 7.80000
Volume2,440,150
Avg. Volume1,498,509
Market Cap4.098M
Beta5.19
PE Ratio (TTM)N/A
EPS (TTM)-4.34900
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology

    InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patents 10,070,976 and 10,070,977 covering InspireMD’s proprietary MicroNet™ stent jacket combined with a stent scaffold and related drug eluting technologies. MicroNet is a key differentiator of InspireMD’s commercial products, including the company’s lead product, CGuard™ EPS, for the prevention of stroke in patients being treated for carotid artery disease.

  • ACCESSWIRE5 days ago

    Today's Research Reports on Trending Tickers: InspireMD and Tandem Diabetes Care

    NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...

  • GlobeNewswire14 days ago

    InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

    TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C. Wainwright 20th Annual Global Investment Conference (previously known as the Rodman and Renshaw conference).  The conference is being held on September 4-6, 2018 at the St. Regis New York in New York City. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the H.C. Wainwright conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • GlobeNewswirelast month

    InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

    TEL AVIV, Israel, Aug. 06, 2018-- InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of carotid artery disease, today announced results ...

  • GlobeNewswire2 months ago

    InspireMD Schedules Second Quarter 2018 Earnings Conference Call

    Tel Aviv, July 31, 2018-- InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it will ...

  • GlobeNewswire2 months ago

    InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence

    The first COE is at the Augusta Hospital Clinic for Vascular Surgery in Düsseldorf, Germany and is led by Prof. Ralf Kolvenbach, Head of the Cardiovascular Diseases Department and Medical Director of the Catholic Hospitals. Prof. Kolvenbach is one of the leading vascular surgeons in Germany and treats a significant number of patients suffering form carotid artery disease.  The second COE is at the Maria Cecilia Hospital, in Cotignola, Italy and is led by Dr. Alberto Cremonesi, Chief of the Cardiovascular Department and a leading interventional cardiologist in Italy, also treating a large number of patients suffering from carotid artery disease.

  • ACCESSWIRE2 months ago

    Free Technical Reports on InspireMD and Three Additional Medical Equipment Equities

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on NSPR sign up now at www.wallstequities.com/registration. Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Appliances & Equipment stocks: Globus Medical Inc. (NYSE: GMED), InspireMD Inc. (NYSE AMER: NSPR), Lantheus Holdings Inc. (NASDAQ: LNTH), and LivaNova PLC (NASDAQ: LIVN).

  • GlobeNewswire3 months ago

    InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

    InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 33,333,333 units at a price to the public of $0.30 per unit. InspireMD expects to receive aggregate gross proceeds of approximately $10 million from the offering, assuming no exercise of the underwriter’s option to purchase additional securities. Each unit contains one share of common stock (or common stock equivalent) and one Series D warrant to purchase one share of common stock.

  • Should You Worry About InspireMD Inc’s (NYSEMKT:NSPR) CEO Salary Level?
    Simply Wall St.3 months ago

    Should You Worry About InspireMD Inc’s (NYSEMKT:NSPR) CEO Salary Level?

    Jim Barry took the helm as InspireMD Inc’s (AMEX:NSPR) CEO and grew market cap to US$8.32M recently. Understanding how CEOs are incentivised to run and grow their company is anRead More...

  • ACCESSWIRE3 months ago

    Free Daily Technical Summary Reports on LivaNova and Three Other Medical Equipment Stocks

    WallStEquities.com monitors four Medical Appliances and Equipment stocks, namely: Globus Medical Inc. (NYSE: GMED), Inspire Medical Systems Inc. (NYSE: INSP), InspireMD Inc. (NYSE AMER: NSPR), and LivaNova PLC (NASDAQ: LIVN). Audubon, Pennsylvania headquartered Globus Medical Inc.'s shares recorded a trading volume of 636,640 shares last Friday.

  • Why You Need To Look At This Factor Before Buying InspireMD Inc (NYSEMKT:NSPR)
    Simply Wall St.4 months ago

    Why You Need To Look At This Factor Before Buying InspireMD Inc (NYSEMKT:NSPR)

    For InspireMD Inc’s (AMEX:NSPR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NSPR is exposed toRead More...

  • ACCESSWIRE5 months ago

    Wired News – InspireMD Received Regulatory Approval to Commercialize its Products in Vietnam

    LONDON, UK / ACCESSWIRE / May 02, 2018 / Active-Investors.com has just released a free research report on InspireMD, Inc. (NYSE: NSPR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NSPR as the Company's latest news hit the wire. On April 30, 2018, the Company announced that it has received regulatory approval and has initiated commercialization of its CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ in Vietnam.

  • Benzinga5 months ago

    InspireMD Stock Rallies After Vietnam Approves Embolism Prevention Products

    InspireMD Inc (NYSE: NSPR ) stock rallied Monday on news of regulatory approval for its products. What Happened InspireMD announced that it received regulatory approval for its CGuard Embolic Prevention ...

  • ACCESSWIRE6 months ago

    Blog Exposure - InspireMD Announced Regulatory Approval for CGuard Embolic Prevention System and MGuard Prime in Peru

    Stock Monitor: Avinger Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on InspireMD, Inc. (NYSE: NSPR ). If you want access ...